Home >> Tag Archives: Nanosphere—

Tag Archives: Nanosphere—

Rapid sepsis test shortens hospital stays

March 29, 2016—A study published in the Archives of Pathology & Laboratory Medicine demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with Nanosphere‘s FDA-cleared Verigene Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population. The outcomes study was conducted at Children’s Hospital Los Angeles. “Our study is the first to assess the clinical and economic ...

Read More »

FDA clears flexible respiratory pathogen test

Sept. 28, 2015—Nanosphere has received Food and Drug Administration 510(k) clearance for its Verigene Respiratory Pathogens Flex Nucleic Acid Test on the automated sample-to-result Verigene System. RP Flex features Nanosphere’s Flex software, which allows the 16 viral and bacterial targets identified by RP Flex to be reported as a full multiplex panel or in various user-defined subsets. Labs pay for ...

Read More »

Verigene BC-GN test, 2/14

February 2014—Nanosphere received FDA clearance for its Verigene Gram-Negative Blood Culture (BC-GN) Test, an in vitro diagnostic test that determines resistance to commonly used antibiotics up to two to three days faster than conventional identification methods. Among the critical genetic markers of antibiotic resistance identified by Verigene BC-GN are five genes that can identify carbapenem-resistant Enterobacteriaceae.

Read More »

Gram-negative blood culture test, 4/13:88

Nanosphere has obtained the CE-IVD Mark for its gram-negative blood culture test (BC-GN) on the automated sample-to-result Verigene system. The test expands Nanosphere’s infectious disease test capabilities to include rapid detection of bacteria that can cause deadly bloodstream infections.

Read More »